The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.